Med24
kliininen-tutkimus 10. 11. 2026 • 2 min read • ClinicalTrials.gov (Ankara Etlik City Hospital)

Comparison of Clinical Outcomes Associated With Different Transcranial Magnetic Stimulation Protocols Combined With Botulinum Toxin-A Injection in Post-Stroke Upper Limb Spasticity

Comparison of Clinical Outcomes Associated With Different Transcranial Magnetic Stimulation Protocols Combined With Botulinum Toxin-A Injection in Post-Stroke Upper Limb Spasticity

Kuva MASLD:stä (metabolinen oireyhtymä-lihasrasvushierova) tyypillisessä diabeteksessa, esimerkinä Kuwaitissa.

Post-stroke upper limb spasticity is an important condition that negatively affects motor recovery, upper limb functions, and activities of daily living. Multimodal treatment approaches are recommended in the management of spasticity. In recent years, the effects of transcranial magnetic stimulation (TMS) on upper limb functions and spasticity have been investigated. However, the clinical effects of different TMS protocols combined with botulinum toxin-A (BTX-A) treatment and which protocol may be more effective remain unclear. The aim of this observational study is to compare the clinical effects of different TMS protocols in patients with post-stroke upper limb spasticity receiving BTX-A treatment and to evaluate the most appropriate TMS protocol. As part of the study, patients who received botulinum toxin type A (BTX-A) injections for upper extremity spasticity following stroke were evaluated using different TMS protocols. All patients received a standard conventional physical therapy program. TMS sessions were conducted using an inhibitory protocol, with a total of 10 sessions administered to the contralateral hemisphere at least 3 days per week. Clinical evaluations were performed at baseline, at 1 month, and at 3 months. Thus, the early and long-term clinical outcomes of treatment were investigated. Spasticity was assessed using the Modified Ashworth Scale (MAS), motor improvement using the Brunnstrom staging system, upper extremity motor function using the Fugl-Meyer Assessment, and upper extremity use in activities of daily living using the Motor Activity Log-28 (MAL-28). Additionally, patients' anxiety and depression levels were measured using the Hospital Anxiety and Depression Scale (HADS).

Sponsored content

Original Scientific Source
ClinicalTrials.gov (Ankara Etlik City Hospital)
View Original Source
Lääketieteellinen vastuuvapauslauseke Kaikki tämän sivuston laskelmat, suositukset ja tulkinnat ovat ainoastaan suuntaa-antavia ja koulutuksellisia. Ne eivät korvaa ammattimaista lääkärintarkastusta, diagnoosia tai hoitoa. Käänny aina lääkärin puoleen terveysasioissa.

Recommended Medical News

All news →
Pembrolizumab Tutkimus: Uusihoito Kolmiotonta Rintasyöpää Varten
kliininen-tutkimus

Pembrolizumab Tutkimus: Uusihoito Kolmiotonta Rintasyöpää Varten

Tässä vaihe III:n kliinisessä tutkimuksessa arvioitiin pembrolizumab-lääkkeen tehoa ja turvallisuutta kolmiotonta rintasyöpää sairaville. Tutkimus rekrytoi 1195 osallistujaa, joilla oli rintasyöpä, mukaan lukien kolmioton ja matala estrogeenireseptorinen/HER2-rajallinen rintasyöpä, neoadjuvantisen kemoterapian jälkeen.

16. 11. 2026 Read article →
Advertisement